ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers

BACKGROUND: Immune checkpoint inhibitors (ICIs) therapy targeting programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) shows promising clinical benefits. However, the relatively low response rate highlights the need to develop an alternative strategy to target PD-1/PD-L1 immune chec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Zheng-Zheng, Liu, Yun-Ya, Zhu, Wei, Xiao, Ding, Huang, Wei, Lu, Shan-Shan, Yi, Hong, Zeng, Ting, Feng, Xue-Ping, Yuan, Li, Qiu, Jie-Ya, Wu, Di, Wen, Qi, Zhou, Jian-Hua, Zhuang, Wei, Xiao, Zhi-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069584/
https://www.ncbi.nlm.nih.gov/pubmed/37001908
http://dx.doi.org/10.1136/jitc-2022-006345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069584/
https://www.ncbi.nlm.nih.gov/pubmed/37001908
http://dx.doi.org/10.1136/jitc-2022-006345

Ejemplares similares